Shenzhen Shenxin Biotechnology Co., Ltd

This study tests a new mRNA vaccine (IN001) to prevent shingles in healthy adults aged 50 to 79. About 480 participants will receive one of three doses of the study vaccine or an existing shingles vaccine. Researchers will check how well the vaccine triggers the immune system and…

This early-stage study tests a new mRNA vaccine called IN006 for respiratory syncytial virus (RSV) in healthy adults aged 18 to 79. The vaccine is given as one shot, with some older adults getting a booster about a year later. The main goal is to check safety and how well the vac…